|1.||Yang, Gengxia: 3 articles (08/2015 - 03/2015)|
|2.||Hao, Meijun: 3 articles (08/2015 - 03/2015)|
|3.||Zheng, Jiasheng: 3 articles (08/2015 - 03/2015)|
|4.||Li, Li: 3 articles (08/2015 - 03/2015)|
|5.||Wu, Xia: 3 articles (08/2015 - 03/2015)|
|6.||Long, Jiang: 3 articles (08/2015 - 03/2015)|
|7.||Hu, Caixia: 3 articles (08/2015 - 03/2015)|
|8.||Sheng, Shoupeng: 3 articles (08/2015 - 03/2015)|
|9.||Zhang, Honghai: 3 articles (08/2015 - 03/2015)|
|10.||Sun, Yu: 3 articles (08/2015 - 03/2015)|
04/01/1983 - "In the TP-1 treated group we observed a significant reduction of infections (P=0.023) in comparison to the control group. "
05/31/1991 - "The present study aimed to assess the effects of thymostimulin in patients with different degrees of immunodepression, by evaluating both the incidence of postoperative infections and the changes induced in various immunological parameters. "
11/01/1986 - "The authors evaluated prospectively, in a controlled, randomized and stratified study, the efficiency of thymostimulin in reducing postoperative infections in 42 such patients. "
06/30/1992 - "The Authors have found a notable reduction of postoperative infection incidence in the 61 anergic operated patients who have been treated with Thymostimulin; they conclude by underlining the importance of careful consideration and eventual correction of immunological alterations of the patients of the patients who must undergo an operation."
06/01/1992 - "Therefore, it is Authors' opinion that the treatment with Thymostimulin in immunocompromised patients is important in order to avoid or reduce postoperative infection rates."
|2.||Hodgkin Disease (Hodgkin's Disease)
01/01/1988 - "A total of 19 Hodgkin's disease (HD) patients (12 male, 7 female) aged 26-67 years, who had been in complete unmaintained remission for 6 months or more when the study was initiated, were randomly given 50 mg thymostimulin (TS) i.m. "
01/01/1988 - "A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin's disease in complete remission."
01/01/1985 - "Fifteen Hodgkin's disease patients (8 male, 7 female) aged 19-72 years, who had been in complete unmaintained remission for 1 year or more when the study was initiated, were given 50 mg thymostimulin (TS) IM daily for 60 consecutive days. "
01/01/1985 - "Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease in clinical remission."
09/01/1983 - "The in vivo effect of thymic factor (thymostimulin) administration in Hodgkin's disease patients. "
03/01/2015 - "This experimental finding suggested that TP-1 exhibited prominent antitumor activities in vivo via enhancement of host immune system function in H22 tumor-bearing mice. "
03/01/2015 - "Besides, the percentage of CD4+ T cells and NK cells was increased, whereas the number of CD8+ T cells decreased in tumor-bearing mice following TP-1 administration. "
02/28/1990 - "The patient, a 58-year-old man, received no specific therapy for his tumor, but only a thymus extract ("thymostimulin"). "
01/01/1989 - "Only complete responders received maintenance treatment, consisting of thymostimulin administered 1 mg/Kg i.m., twice weekly, until tumor relapse. "
07/01/1987 - "Modulation of immune response and tumor development in tumor-bearing mice treated by the thymic factor thymostimulin."
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
01/01/1984 - "The use of thymostimulin induced the treated children more readily than the untreated ones to show improvement in both the score for respiratory infections and the distribution of T-cell subsets."
08/01/1993 - "Effectiveness of thymostimulin and study of lymphocyte-dependent antibacterial activity in children with recurrent respiratory infections."
01/01/1984 - "T lymphocytes in children with recurrent respiratory infections: effect of the use of thymostimulin on the alterations of T-cell subsets."
11/01/1988 - "Numerous trials of prophylaxis of recurrent respiratory infections in children have been performed, even though the only controlled trials providing incontrovertible results were the ones carried out with levamisole and thymostimulin through intramuscular administration. "
01/01/1981 - "The Authors wish to examine the protective effects which a period of pre-treatment with thymostimulin, would have on endotoxin hepatitis, induced in thymectomized and non-thymectomized animals. "
01/01/1984 - "The authors carried out a controlled therapeutic trial with Thymostimulin in 43 drug addicts affected by acute type B anti-Delta negative viral hepatitis. "
10/31/1987 - "[Can thymostimulin influence the course of malignant subacute hepatitis?]."
01/01/1985 - "Activity of a bovine thymic extract (thymostimulin) in mouse subacute experimental hepatitis: biochemical, immunological and histological findings."
01/01/1984 - "[Treatment of chronic active HBsAg-positive hepatitis with thymostimulin]."
|4.||Leucovorin (Folinic Acid)
|5.||Antiviral Agents (Antivirals)
|8.||Hepatitis B Surface Antigens (HBsAg)
|9.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|10.||Granulocyte Colony-Stimulating Factor (G-CSF)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)